References
- Karlan B, Markman M, Eifel P. Gynecologic cancers. In: DeVita V, Hellman S, Rosenberg S, editors. Principles and practice of oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
- Beitelshees AL, Veenstra DL. Evolving research and stakeholder perspectives on pharmacogenomics. JAMA 2011;306: 1252–3.
- Schneider B, Li K, Miller K, Flockhart DA, Radovich M, Hancock BA, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstracts Suppl abstract 1000[29] 2011.
- Bergmann TK, Brasch-Andersen C, Green H, Mirza MR, Pedersen RS, Nielsen F, et al. Impact of CYP2C8*3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011;11:113–20. Epub 2010 Apr 6.
- Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011;67:693–700.
- Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104:130–7.
- Online Mendelian Inheritance in Man. 2012. [cited 28 Mar 2012]. Available from: http://www.omim.org/entry/602574.